Comparable stake leader
Orca Capital AG
SEC ownership of AIM ImmunoTech Inc.
Top holders, 13D/G large-stake signals, insider positions, and transaction flow tied to CIK 0000946644.
Disclosed value leader
ARMISTICE CAPITAL, LLC
Comparable rows
5/29
Latest evidence
07 May 2026
- Public ticker
- AIM on NYSE
- Parsed ownership sources
-
13D/G, 3/4/5, and 13F
Source: Parsed SEC ownership filingsUse: Compare filing families carefully
- Largest SEC-reported holder
-
Orca Capital AG
Ranking: Comparable ownership first, then disclosed value
- Comparable ownership rows
-
5 of 29
Meaning: Rows with safely comparable ownership %
- Latest 13D/G holder
-
Orca Capital AG
Source: Latest parsed Schedule 13D/G stake
- Latest parsed ownership date
-
07 May 2026
Freshness: Most recent filing date in this holder set
- Issuer CIK
- 0000946644
- Issuer location
- Ocala, FL
Ownership snapshot
CIK-linked ownership evidence from parsed SEC filings.
3 signals
Issuer
Names, identifiers, and filing context for this profile.
2 identity fields
Ownership snapshot
Top shareholders of AIM ImmunoTech Inc. (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
Orca Capital AG
Disclosed value leader
ARMISTICE CAPITAL, LLC
Comparable rows
5/29
Latest evidence
07 May 2026
13D/G
3/4/5
13F
Lead comparable stake: 9.9%
24 rows are not safely comparable across share classes.
13D/G row: Orca Capital AG
Showing 1-8 of 29 holder rows.
Quick read
Orca Capital AG leads the comparable SEC ownership view at 9.9%.
5 of 29 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens Orca Capital AG's linked filing trail.
Comparable ownership
Top 5
Orca Capital AG
9.9%
ARMISTICE CAPITAL, LLC
5%
Todd Deutsch
2.7%
William M. Mitchell
2.9%
Ted D. Kellner
0.21%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-8 of 29 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| Orca Capital AG |
13D/G
|
9.9%
|
$125,580
1,793,999 shares
|
$0 | 07 May 2026 |
| ARMISTICE CAPITAL, LLC |
13D/G
|
5%
|
$200,984
3,349,740 shares
|
$0 | 31 Dec 2024 |
| Todd Deutsch |
13D/G
|
2.7%
|
$102,966
1,716,100 shares
|
$0 | 19 Dec 2024 |
| William M. Mitchell |
3/4/5
Director
|
2.9%
|
$13,297
522,103 shares
|
— | 21 Apr 2025 |
| Ted D. Kellner |
3/4/5
Director
|
0.21%
|
$2,603
37,205 shares
|
— | 17 Jul 2025 |
| Stewart Appelrouth |
3/4/5
Director
|
—
class O/S missing
|
$76,968
388,729 shares
|
— | 31 Dec 2024 |
| Thomas K. Equels |
3/4/5
CEO & President, Director
|
—
mixed-class rows
|
$50,498
113,922 shares
mixed-class rows
|
— | 16 Mar 2026 |
| Peter W. Rodino III |
3/4/5
COO, Secretary, Gen. Counsel
|
—
class O/S missing
|
$34,953
401,762 shares
|
— | 04 Apr 2025 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
Forms 3/4/5 flow
Insider trading overview
Insider buy and sell flow is broadly balanced over the last 12 months. No Buy or Sell transactions have been reported since 27 Jun 2025.
Buys
$0
Insiders: 0
Sells
$0
Insiders: 0
Net
$0
Shares: 0
Window
Last 12 months
4 rolling buckets
Buy value
Sell value
Shares: 0
Shares: 0
| Window (months) | Buy shares | Sell shares | Buy value | Sell value | Net value |
|---|---|---|---|---|---|
| 0-3 | 0 | 0 | $0 | $0 | $0 |
| 3-6 | 0 | 0 | $0 | $0 | $0 |
| 6-9 | 0 | 0 | $0 | $0 | $0 |
| 9-12 | 0 | 0 | $0 | $0 | $0 |
Reporting owners
Insider holders from Forms 3/4/5
Showing 1-9 of 9 reporting-owner rows connected to AIM ImmunoTech Inc.. Open a relationship link for the CIK-to-CIK filing trail.
Rows
9
Largest Forms 3/4/5 holder
Stewart Appelrouth
Net 12M change
$0
Latest report
16 Mar 2026
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Valuation | Report Date |
|---|---|---|---|---|---|---|
| Stewart Appelrouth | Director | $76,968 | Mixed | 31 Dec 2024 | ||
| Thomas K. Equels | CEO & President, Director | $50,498 | Mixed | 16 Mar 2026 | ||
| Peter W. Rodino III | COO, Secretary, Gen. Counsel | $34,953 | Filing P/S | 04 Apr 2025 | ||
| Nancy Bryan | Director | $33,858 | Mixed | 14 Mar 2025 | ||
| David I. Chemerow | Director | $22,468 | Mixed | 16 Mar 2026 | ||
| William M. Mitchell | Director | $13,297 | Mixed | 21 Apr 2025 | ||
| Ted D. Kellner | Director | $2,603 | Mixed | 17 Jul 2025 | ||
| Ellen M. Lintal | Former Chief Financial Officer | Mixed | 04 Apr 2022 | |||
| Robert Dickey IV | Chief Financial Officer | Mixed | 04 Apr 2022 |
Recent insider transactions for AIM ImmunoTech Inc.
Showing up to 300 recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | SEC-reported value | SEC-reported price | Shares | Shares owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| Thomas K. Equels | AIM | Common stock | Conversion of derivative security | 64.2% | 25,000 | 63,922 | 12 Mar 2026 | Direct | ||
| Thomas K. Equels | AIM | Series G Convertible Preferred Stock | Conversion of derivative security | -100% | -25 | 0 | 12 Mar 2026 | Direct | ||
| David I. Chemerow | AIM | Common Stock | Conversion of derivative security | 726.5% | 25,000 | 28,441 | 12 Mar 2026 | Direct | ||
| David I. Chemerow | AIM | Series G Convertible Prefered Stock | Conversion of derivative security | -100% | -25 | 0 | 12 Mar 2026 | Direct | ||
| Thomas K. Equels | AIM | Class G Warrants | Other | 50,000 | 50,000 | 06 Mar 2026 | Direct | |||
| Thomas K. Equels | AIM | Series G Convertible Preferred Stock | Other | 25 | 25 | 06 Mar 2026 | Direct | |||
| David I. Chemerow | AIM | Class G Warrants | Other | 50,000 | 50,000 | 06 Mar 2026 | Direct | |||
| David I. Chemerow | AIM | Series G Convertible Preferred Stock | Other | 25 | 25 | 06 Mar 2026 | Direct | |||
| David I. Chemerow | AIM | Common Stock | Award | 436.8% | 2,800 | 3,441 | 05 Feb 2026 | The David I Chemerow 1992 Trust |
* marks a reported price that did not pass the local price check.